FindTrial
Sign In

A study in lung cancer patients for understanding distinct genetic characteristics for better diagnostics

Study to assess circulating free nucleic acids in diagnosed lung cancer subjects for prognostic biomarker/s

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/08/056271
Enrollment
330
Registered
2023-08-08
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Avesthagen Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Male and female subjects diagnosed from lung cancer between the age of 40 to 65 years (both inclusive)

Exclusion criteria

Exclusion criteria: Diagnosed with any other cancer along with lung cancer. Pregnant and lactating women need to be excluded from the study.

Design outcomes

Primary

MeasureTime frame
Aged-matched to predict biomarkers for lung cancer similar to epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), along with othersTimepoint: On the day of enrollment to this study—

Secondary

MeasureTime frame
Current & past health status assessed via Health QuestionnaireTimepoint: Baseline & at 7±1 day—

Countries

India

Contacts

Public ContactDivya Chandradhara

BioAgile Therapeutics Pvt Ltd

divya@bioagiletherapeutics.com9538961761

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026